FDC Ltd Q2 FY27 results are out (Jul–Sep 2026) →Revenue ₹572 Cr +20.9% YoYSee revenue, profit and what management said. You are viewing Q3 FY23.
F

FDC Ltd

Q3 FY23Pharmaceuticals & Biotechnology

FDC Q3 FY23: Revenue ₹407 Cr, PAT ₹41 Cr

Q3 FY23 investor presentation: what the company reported on revenue, margins and capex.

Based on FDC Ltd's Q3 FY23 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹346
Market cap₹5.7K Cr
P/E18.6

The short version

Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13). EBITDA for Q3FY23: ₹65 crore, up 15% YoY from ₹57 crore in Q3FY22 - Operating Expenses for Q3FY23: ₹360 crore, up 21% YoY from ₹298 crore in Q3FY22 - Profit After Tax (PAT) for Q3FY23: ₹41 crore, up 26% YoY from ₹32 crore in Q3FY22 - Revenue from operations for Q3FY23: ₹407 crore, up 19% YoY from ₹341 crore in Q3FY22 - EPS for Q3FY23: ₹2.38, up 27% YoY from ₹1.87 in Q3FY22

From FDC Ltd's Q3 FY23 earnings-call transcript · updated 25 Sept 2026.

Revenue & Sales Performance

  • Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13).
  • Total Income Q3FY23: ₹425 crores, up 20% YoY from ₹354 crores (Page 13).
  • Domestic sales Q3FY23: ₹318 crores with 10% YoY growth (Page 4).
  • Export sales Q3FY23: ₹92 crores with 71% YoY growth (Page 4).

2 more points from FDC Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

EBITDA for Q3FY23: ₹65 crore, up 15% YoY from ₹57 crore in Q3FY22

Locked: what FDC Ltd said on margins

Also locked on this page: fundraising, order book

Free account, 30 seconds. No card needed.

Capital Expenditure Plans

It mentions: - Strong manufacturing facilities across multiple locations (Baddi, Goa, Waluj, Sinnar, Roha) with various plants for formulations, APIs, and foods (Page 10). - High-quality manufacturing capabilities supporting exports to over 50 countries (Page 3).

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

All data related to finance costs are internal and no fundraising announcements are included.

Locked: what FDC Ltd said on fundraising

Also locked on this page: margins, order book

Free account, 30 seconds. No card needed.

Order Book & Pipeline

See what FDC Ltd said on order book & pipeline — free account, 30 seconds.

FDC Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹572 Cr, net profit ₹49 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Anuh Pharma (Q3 FY23)

    138.73 Cr, up 21% QoQ (from Rs. Key concall takeaways from Anuh Pharma Ltd's Q3 FY23 earnings call — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

FDC Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were FDC Ltd Q3 FY23 results?

Q3FY23 Revenue from operations: ₹407 crores, up 19% YoY from ₹341 crores in Q3FY22 (Page 13). EBITDA for Q3FY23: ₹65 crore, up 15% YoY from ₹57 crore in Q3FY22 - Operating Expenses for Q3FY23: ₹360 crore, up 21% YoY from ₹298 crore in Q3FY22 - Profit After Tax (PAT) for Q3FY23: ₹41 crore, up 26% YoY from ₹32 crore in Q3FY22 - Revenue from operations for Q3FY23: ₹407 crore, up 19% YoY from ₹341 crore in Q3FY22 - EPS for Q3FY23: ₹2.38, up 27% YoY from ₹1.87 in Q3FY22

What is FDC Ltd share price analysis?

FDC Ltd currently shows a neutral. The stock trades at a P/E of 18.6 with a market cap of ₹5,739 Cr. Investors should review the full earnings analysis for detailed insights.

Keep FDC Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.